☰

Jan van de Winkel - Publications

Affiliations: 
Immunology University Medical Center Utrecht, Utrecht, Netherlands 
Area:
Immunotherapy
Tree Info Similar researchers PubMed Report error

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 5: e1058459. PMID 26942070 DOI: 10.1080/2162402X.2015.1058459  0.339
2014 Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science (New York, N.Y.). 343: 1260-3. PMID 24626930 DOI: 10.1126/Science.1248943  0.509
2013 Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, et al. IgA EGFR antibodies mediate tumour killing in vivo. Embo Molecular Medicine. 5: 1213-26. PMID 23918228 DOI: 10.1002/emmm.201201929  0.401
2013 Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA. Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions. Journal of Immunology (Baltimore, Md. : 1950). 191: 353-62. PMID 23740955 DOI: 10.4049/jimmunol.1203243  0.348
2013 Labrijn AF, Meesters JI, De Goeij BECG, Van Den Bremer ETJ, Neijssen J, Van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, Van Berkel PHC, Van De Winkel JGJ, Schuurman J, Parren PWHI. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Proceedings of the National Academy of Sciences of the United States of America. 110: 5145-5150. PMID 23479652 DOI: 10.1073/pnas.1220145110  0.44
2011 Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 96: 1822-30. PMID 21880632 DOI: 10.3324/haematol.2011.047159  0.367
2011 Overdijk MB, Verploegen S, Van Den Brakel JH, Lammerts Van Bueren JJ, Vink T, Van De Winkel JGJ, Parren PWHI, Bleeker WK. Epidermal growth factor receptor (EGFR) Antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition Journal of Immunology. 187: 3383-3390. PMID 21832160 DOI: 10.4049/jimmunol.1003926  0.325
2011 Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, Parren PW. Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nature Biotechnology. 29: 574-6. PMID 21747378 DOI: 10.1038/nbt.1912  0.31
2011 Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science. 102: 1761-8. PMID 21718386 DOI: 10.1111/j.1349-7006.2011.02019.x  0.402
2011 Peipp M, van de Winkel JG, Valerius T. Molecular engineering to improve antibodies' anti-lymphoma activity. Best Practice & Research. Clinical Haematology. 24: 217-29. PMID 21658620 DOI: 10.1016/j.beha.2011.03.004  0.448
2011 Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. Journal of Immunology (Baltimore, Md. : 1950). 186: 3770-8. PMID 21317397 DOI: 10.4049/jimmunol.1003082  0.424
2010 van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, Leusen JH. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood. 116: 5327-33. PMID 20805361 DOI: 10.1182/blood-2010-04-280214  0.357
2010 de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Research. 70: 3209-17. PMID 20354182 DOI: 10.1158/0008-5472.CAN-09-4109  0.349
2010 Schneider-Merck T, Van Lammerts Bueren JJ, Berger S, Rossen K, Van Berkel PHC, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PWHI, Van De Winkel JGJ, Valerius T, Dechant M. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage Journal of Immunology. 184: 512-520. PMID 19949082 DOI: 10.4049/jimmunol.0900847  0.344
2010 van de Winkel JG. Fc receptors: role in biology and antibody therapy. Immunology Letters. 128: 4-5. PMID 19808048 DOI: 10.1016/j.imlet.2009.09.005  0.441
2010 van Berkel PH, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JG, Parren PW. Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. Biotechnology and Bioengineering. 105: 350-7. PMID 19739094 DOI: 10.1002/bit.22535  0.352
2009 Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology. 27: 767-71. PMID 19620983 DOI: 10.1038/Nbt.1553  0.454
2009 van Berkel PH, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JG, Parren PW. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnology Progress. 25: 244-51. PMID 19224598 DOI: 10.1002/btpr.92  0.327
2008 Beurskens FJ, Ruuls SR, Engelberts PJ, Vink T, Mackus WJ, van de Winkel JG, Parren PW. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood. 112: 4354-5; author reply. PMID 18988880 DOI: 10.1182/blood-2008-07-171082  0.311
2008 Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnology Journal. 3: 1157-71. PMID 18702090 DOI: 10.1002/biot.200800110  0.466
2008 Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts Van Bueren JJ, Bleeker WK, Parren PWHI, Van De Winkel JGJ, Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies Cancer Research. 68: 4998-5003. PMID 18593896 DOI: 10.1158/0008-5472.CAN-07-6226  0.443
2008 Peipp M, Van Bueren JJL, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, Repp R, Van Berkel PHC, Vink T, Van De Winkel JGJ, Parren PWHI, Valerius T. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells Blood. 112: 2390-2399. PMID 18566325 DOI: 10.1182/blood-2008-03-144600  0.481
2008 Bleeker WK, Munk ME, Mackus WJM, Van Den Brakel JHN, Pluyter M, Glennie MJ, Van De Winkel JGJ, Parren PWHI. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody British Journal of Haematology. 140: 303-312. PMID 18045353 DOI: 10.1111/j.1365-2141.2007.06916.x  0.343
2007 Kolfschoten MVDN, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, Den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, Van De Winkel JGJ, Aalberse RC, Parren PWHI. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange Science. 317: 1554-1557. PMID 17872445 DOI: 10.1126/science.1144603  0.462
2007 Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, Van De Winkel JGJ, Valerius T. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor Journal of Immunology. 179: 2936-2943. PMID 17709508  0.342
2007 McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond M, Leusen JH, Lazarou M, van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass RJ. The importance of human FcgammaRI in mediating protection to malaria. Plos Pathogens. 3: e72. PMID 17511516 DOI: 10.1371/journal.ppat.0030072  0.37
2007 van Sorge NM, Yuki N, Jansen MD, Nishimoto Y, Susuki K, Wokke JH, van de Winkel JG, van den Berg LH, van der Pol WL. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. Journal of Neuroimmunology. 182: 116-23. PMID 17161468 DOI: 10.1016/J.Jneuroim.2006.10.005  0.625
2007 van Sorge NM, Yuki N, Koga M, Susuki K, Jansen MD, van Kooten C, Wokke JH, van de Winkel JG, van der Pol WL, van den Berg LH. Ganglioside-specific IgG and IgA recruit leukocyte effector functions in Guillain-Barré syndrome. Journal of Neuroimmunology. 182: 177-84. PMID 17156858 DOI: 10.1016/J.Jneuroim.2006.10.015  0.651
2006 Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 108: 3573-9. PMID 16849638 DOI: 10.1182/blood-2006-05-024539  0.39
2006 Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research. 66: 1261-4. PMID 16452176 DOI: 10.1158/0008-5472.CAN-05-2856  0.433
2006 Steeghs L, van Vliet SJ, Uronen-Hansson H, van Mourik A, Engering A, Sanchez-Hernandez M, Klein N, Callard R, van Putten JP, van der Ley P, van Kooyk Y, van de Winkel JG. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cellular Microbiology. 8: 316-25. PMID 16441441 DOI: 10.1111/j.1462-5822.2005.00623.x  0.469
2006 Rodríguez ME, Hellwig SMM, Pérez Vidakovics MLA, Berbers GAM, Van De Winkel JGJ. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies Fems Immunology and Medical Microbiology. 46: 39-47. PMID 16420595 DOI: 10.1111/j.1574-695X.2005.00001.x  0.476
2006 Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T. Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity. British Journal of Haematology. 132: 317-25. PMID 16409296 DOI: 10.1111/J.1365-2141.2005.05884.X  0.324
2005 Vidarsson G, Overbeeke N, Stemerding AM, van den Dobbelsteen G, van Ulsen P, van der Ley P, Kilian M, van de Winkel JG. Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infection and Immunity. 73: 6721-6. PMID 16177349 DOI: 10.1128/IAI.73.10.6721-6726.2005  0.366
2005 Van Royen-Kerkhof A, Sanders EAM, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, Gerritsen A, Van Dijk MA, Kuis W, Rijkers GT, Vitale L, Keler T, McKenzie SE, Leusen JHW, Van De Winkel JGJ. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice British Journal of Haematology. 130: 130-137. PMID 15982355 DOI: 10.1111/j.1365-2141.2005.05571.x  0.458
2005 Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. Journal of Immunology (Baltimore, Md. : 1950). 174: 5472-80. PMID 15843545  0.305
2005 Breij EC, Heijnen P, Vloet R, Saito T, van de Winkel JG, Dijkstra CD, Amor S, Verbeek S. The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE. Journal of Neuropathology and Experimental Neurology. 64: 304-11. PMID 15835266  0.393
2005 van Sorge NM, van der Pol WL, Jansen MD, Geleijns KP, Kalmijn S, Hughes RA, Rees JH, Pritchard J, Vedeler CA, Myhr KM, Shaw C, van Schaik IN, Wokke JH, van Doorn PA, Jacobs BC, ... van de Winkel JG, et al. Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. Journal of Neuroimmunology. 162: 157-64. PMID 15833371 DOI: 10.1016/J.Jneuroim.2005.01.016  0.612
2004 Kobayashi T, Takauchi A, van Spriel AB, Vilé HA, Hayakawa M, Shibata Y, Abiko Y, van de Winkel JG, Yoshie H. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils. Vaccine. 23: 585-94. PMID 15542178 DOI: 10.1016/j.vaccine.2004.07.015  0.48
2004 Bleeker WK, Lammerts Van Bueren JJ, Van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, Van Dijk MA, Van De Winkel JGJ, Parren PWHI. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy Journal of Immunology. 173: 4699-4707. PMID 15383606  0.327
2004 Bouts AH, Krediet RT, Davin JC, Monnens LA, Nauta J, Schröder CH, van de Winkel JG, Out TA. IGG and complement receptor expression on peripheral white blood cells in uraemic children. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 19: 2296-301. PMID 15266033 DOI: 10.1093/ndt/gfh402  0.312
2003 Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Molecular Immunology. 40: 585-93. PMID 14597161  0.402
2003 van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Research. 63: 5595-600. PMID 14500400  0.304
2003 Hellwig SMM, Rodriguez ME, Berbers GAM, Van De Winkel JGJ, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity Journal of Infectious Diseases. 188: 738-742. PMID 12934190 DOI: 10.1086/377283  0.494
2003 Pleass RJ, Ogun SA, McGuinness DH, van de Winkel JG, Holder AA, Woof JM. Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. Blood. 102: 4424-30. PMID 12855589 DOI: 10.1182/blood-2003-02-0583  0.409
2003 Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discovery Today. 8: 503-10. PMID 12818520  0.379
2003 Saeland E, Leusen JHW, Vidarsson G, Kuis W, Sanders EAM, Jonsdottir I, Van De Winkel JGJ. Role of leukocyte immunoglobulin G receptors in vaccine-induced immunity to Streptococcus pneumoniae Journal of Infectious Diseases. 187: 1686-1693. PMID 12751025 DOI: 10.1086/375276  0.354
2003 van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, Thepen T, van de Winkel JG. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis and Rheumatism. 48: 1229-38. PMID 12746896 DOI: 10.1002/art.10940  0.402
2003 van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Annals of Neurology. 53: 570-9. PMID 12730990 DOI: 10.1002/Ana.10503  0.646
2003 van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood. 101: 253-8. PMID 12485936 DOI: 10.1182/blood.V101.1.253  0.355
2002 Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van De Winkel JG, Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood. 100: 4574-80. PMID 12393717 DOI: 10.1182/blood-2002-03-0687  0.43
Show low-probability matches.